MOLECULAR PATHWAYS OF DISEASE AND NOVEL THERAPEUTIC TARGETS

Abstract

The global burden of disease remains increasingly complex, driven by population ageing, epidemiological transition, environmental exposures, and the rising prevalence of chronic, multifactorial disorders. Recent Global Burden of Disease estimates demonstrate that hundreds of diseases and injuries continue to generate mortality, disability, and loss of healthy life worldwide, with inequities between populations (GBD 2023 Diseases and Injuries Collaborators, 2025). Beyond clinical consequences, these conditions impose socioeconomic costs through prolonged treatment, reduced productivity, caregiver burden, and escalating pressure on health systems. Current therapies have improved survival and symptom control; however, many remain insufficiently effective because they are designed around broad diagnostic categories rather than the heterogeneous molecular mechanisms operating within individual patients. Treatment resistance, adverse effects, delayed diagnosis, and limited access further widen the gap between therapeutic availability and clinical benefit (Chikowore et al., 2021; Wang & Wang, 2023). Precision medicine addresses this unmet need by integrating molecular phenotyping, biomarkers, and patient-specific characteristics to identify biologically distinct disease subtypes and guide targeted intervention across diverse clinical populations (Mendez et al., 2025). Understanding dysregulated signaling pathways is therefore essential for revealing disease-driving mechanisms, predicting treatment response, and developing therapeutics that modify pathological processes rather than merely suppress symptoms